CCNE1 Amplification clinical trials at UCSF
2 research studies open to eligible people
CCNE1 amplification is when cells have too many copies of the CCNE1 gene. UCSF is testing new drugs for people with advanced solid tumors. These trials look at how safe the drugs are and how they work in the body.
(VELA) Study of BLU-222 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
San Francisco, California and other locations
NKT3447 for Adults with Advanced/Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).
San Francisco, California and other locations
Last updated: